# US 2013/0296330 A1 · Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296330 A1
- Document ID: US20130296330A1
- Status: Published application
- Kind: A1
- Application number: 13/980,063
- Filed: 2012-02-08
- Published: 2013-11-07
- Earliest claimed: 2011-02-14
- Assignees: Elanco Animal Health Ireland Limited
- Inventors: Johannes Wilhelmus J. Thuring
- Web page: https://patentgrep.com/patent/US20130296330A1

## CPC

- C07D 471/18: Bridged systems
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/4995: Pyrazines or piperazines forming part of bridged ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/22: in which the condensed systems contains four or more hetero rings
- C07D 498/22: in which the condensed system contains four or more hetero rings
- C07D 513/18: Bridged systems
- C07D 515/18: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention concerns to naphthyridin derivatives of formula (I) for use in the treatment or prevention of feline immunodeficiency virus (FIV). Furthermore the present invention relates to a method of treating or preventing infection of feline immunodeficiency virus in a feline animal wherein said method comprises the administration to said feline animal of a therapeutically effective amount of a naphthyridin derivative.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A method of treating or preventing feline immunodeficiency virus in a feline animal comprising administering to said feline animal a therapeutically effective amount of a compound of formula (I), including the stereochemically isomeric forms thereof, or a pharmaceutically acceptable salt thereof,
wherein
W is —NH—, —N(CH3)— or piperazine,
X is a bond, —C(═O)— or —S(═O)2—,
Y is C3-7alkylene, and
Z is —NH—C(═O)— or —O—;
and optionally one or more anti-viral agents.

### Claim 13 (depends on 12)

The method according to claim 12 wherein W is —NH— or —N(CH3)—.

### Claim 14 (depends on 12)

The method according to claim 12 wherein X is a bond or —S(═O)2—.

### Claim 15 (depends on 12)

The method according to claim 12 wherein Y is C4-5alkylene.

### Claim 16 (depends on 12)

The method according to claim 12 wherein X is —C(═O)— and Y is C3-4alkylene when W is piperazine.

### Claim 17 (depends on 12)

The method according to claim 12 wherein Z is —O—.

### Claim 18 (depends on 12)

The method according to claim 12 wherein Z is —NH—C(═O)—.

### Claim 19 (depends on 12)

The method according to claim 12 wherein the —W—X—Y—Z— linker is 8 or 9 atoms long.

### Claim 20 (depends on 12)

The method according to claim 12 wherein —W—X—Y—Z— is selected from
- - - NH—C5-7alkylene-NH—C(═O) - - - ,
- - - N(CH3)—S(═O)2— C4-5alkylene-NH—C(═O) - - - ,
- - - N(CH3)—S(═O)2—C4-5alkylene-O - - - ,

### Claim 21 (depends on 12)

The method according to claim 12 wherein the compound of Formula (I) is

### Claim 22 (depends on 12)

The method according to claim 12 wherein said compound of formula (I) is:
or a pharmaceutically acceptable salt thereof.

### Claim 23

A product comprising a compound of the formula
wherein
W is —NH—, —N(CH3)— or piperazine,
X is a bond, —C(═O)— or —S(═O)2—,
Y is C3-7alkylene, and
Z is —NH—C(═O)— or —O—;
and an anti-viral agent as a combined preparation for simultaneous, separate or sequential use in the treatment or prophylaxis of feline immunodeficiency virus.

### Claim 24

A product comprising a compound of the formula
wherein
W is —NH—, —N(CH3)— or piperazine,
X is a bond, —C(═O)— or —S(═O)2—,
Y is C3-7alkylene, and
Z is —NH—C(═O)— or —O—;
and an anti-viral agent as a combined preparation for simultaneous, separate or sequential use in the treatment or prophylaxis of feline immunodeficiency virus.
